Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 vs China-approved Remicade in Active Rheumatoid Arthritis
NCT03707535Phase 3Completed
- Sponsor
- Celltrion
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab-dyyb in rheumatoid arthritis (RA), sponsored by Celltrion. Started Nov 2018; status: completed.
02
Drugs
infliximab-dyyb
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03707535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707535.